SAN FRANCISCO, Feb. 19, 2014 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) will announce its financial results for
the fourth quarter and year-ended December
31, 2013 on Wednesday, February 26,
2014, after the close of U.S.-based financial markets.
Howard Robin, president and chief
executive officer, will host a conference call to review the
results beginning at 5:00 p.m. Eastern
Time (ET)/2:00 p.m. Pacific
Time (PT).
The press release and a live audio-only Webcast of the
conference call can be accessed through a link that is posted on
the home page and Investor Relations section of the Nektar website:
http://www.nektar.com. The web broadcast of the conference call
will be available for replay through Monday,
March 31, 2014.
|
To access the
conference call, follow these instructions:
|
|
|
|
Dial: (877) 881-2183
(U.S.); (970) 315-0453 (international)
|
|
Passcode:
72309374 (Nektar Therapeutics is the host)
|
In the event that any non-GAAP financial measure is discussed on
the conference call that is not described in the press release, or
explained on the conference call, related information will be made
available on the Investor Relations page at the Nektar website as
soon as practical after the conclusion of the conference call.
About Nektar
Nektar Therapeutics (NASDAQ: NKTR) is a
biopharmaceutical company developing novel therapeutics based on
its PEGylation and advanced polymer conjugation technology
platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in oncology, pain and other therapeutic
areas. In the area of pain, Nektar has an exclusive worldwide
license agreement with AstraZeneca for naloxegol (NKTR-118), an
investigational drug candidate, which has been filed for regulatory
approvals in the U.S., Europe and
Canada as a once- daily, oral
tablet for the treatment of opioid-induced constipation. This
agreement also includes NKTR-119, an earlier stage development
program that is a co-formulation of naloxegol and an opioid.
NKTR-181, a novel mu-opioid analgesic molecule for chronic pain
conditions, has completed Phase 2 development in osteoarthritis
patients with chronic knee pain. NKTR-171, a new sodium channel
blocker being developed as an oral therapy for the treatment of
peripheral neuropathic pain, is in Phase 1 clinical development. In
oncology, etirinotecan pegol (NKTR-102) is being evaluated in a
Phase 3 clinical study (the BEACON study) for the treatment of
metastatic breast cancer and is also in Phase 2 studies for the
treatment of ovarian, colorectal, lung and brain cancers. In
anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by
Bayer Healthcare as an adjunctive treatment for intubated and
mechanically ventilated patients with Gram-negative pneumonia.
Additional development-stage products that leverage Nektar's
proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated
rFVIII program, which is in Phase 3 clinical development for
patients with hemophilia A.
Nektar's technology has enabled eight approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
UCB's Cimzia® for Crohn's disease and rheumatoid
arthritis, Roche's PEGASYS® for hepatitis C and Amgen's
Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
SOURCE Nektar Therapeutics